Loading…
Transcript

ICH Guidelines

FDA Tests

  • Monoclonal antibodies are derived by recombinant DNA
  • Cell line should follow ICH Q5B & ICH Q5D
  • CHO cell line is derived from animals so production should also be subject to ICH Q5A
  • Q5A: guidelines concerning “viral safety evaluation of biotechnology products derived from animal cells of human or animal origin.”
  • These ICH guidelines were important for establishing the production quality of Herceptin and establishing what the acceptance criteria for each batch would be.
  • Identity – is it the right drug as indicated on the label?
  • Quantity– how much drug is there and is it consistent with the labeled amount?
  • Impurities – are there process impurities or degradation impurities?
  • Dissolution – does the active ingredient dissolve out of the dosage unit so that the drug is available for the body to absorb?

ICH Guidelines

Quality Control And Validation

  • Active pharmaceutical ingredient in Herceptin is a monoclonal antibody
  • Several sections of ICH guidelines are for its development and production
  • Monoclonal antibodies should be fully characterized and their binding properties and specifications known
  • ICH Q6B lays out what needs to be known about a monoclonal antibody in order to be approved
  • Gives “guidance on justifying and setting specifications for proteins and polypeptides”-ICH Q6B
  • Guideline states characterization of monoclonal antibody should include: biological activity, purity, impurity, quantity, and immunochemical and physicochemical properties.

Acceptance Criteria for Batch Approval

  • Lot retained as reference sample
  • Used to for acceptable comparison
  • In order to receive COA must match reference sample
  • First Herceptin reference sample was Lot HER 1097-3
  • Appearance
  • color, opalescence, & clarity
  • Identity
  • correct protein sequence
  • Purity
  • free of unwanted substances
  • Safety
  • microbial contaminate free
  • Potency
  • relative to standard
  • Bond Affinity
  • strength of monoclonal antibody bonds
  • General
  • osmolality, pH

Herceptin

Trastuzumab

Trastuzumab

  • Trastuzumab produced by CHO cells

  • Trastuzumab is a humanized monoclonal antibody

  • Binds to HER2 on breast cancer cells

  • Human framework region with murine binding regions

  • Stops HER2 from signaling cells to grow

Herceptin

  • Active substance: trastuzumab

  • 150 mg trastuzumab, 3.36mg L - Histidine HCl, 2.16 mg L-Histidine, 136.2mg Trehalose dihydrate, and .6 mg Polysorbate 20

  • Finished product a lyophilised powder concentrate

Trastuzumab bound to HER2

Breast Cancer

Symptoms

HER2+ Breast Cancer

  • Estimated 231,840 new cases invasive breast cancer to be diagnosed in women in the U.S. in 2015,
  • 60,290 new cases of non-invasive breast cancer.
  • 2,350 new cases invasive breast cancer expected in men in 2015
  • Man’s lifetime risk of breast cancer is about 1 in 1,000
  • Breast cancer is the 2nd most commonly diagnosed cancer among American women
  • Estimated that about 30% newly diagnosed cancers in women will be breast cancers

•Lumps or masses in the breast

•Swelling part(s) of a breast

•Skin irritation or dimpling

•Breast or nipple pain

•Nipple retraction (inverted nipple)

•Nipple discharge other than when pregnant

HER2+

Trastuzumab HER2 Interaction

  • Less sensitive to hormone therapy
  • More aggressive because HER2 overproduction stimulates growth
  • Immunohistochemistry tests for cell expression levels of the HER2 receptor

-scores 0-3

-HER2+ scores a 3

  • Herceptin treats HER2+ Breast Cancer and Stomach Cancer
  • 12% of women will develop breast cancer
  • 20% of breast cancers are HER2+
  • HER2+ is overproduction of Human Epidermal Growth Factor Receptor

Assays

  • Potency
  • relative to reference standard
  • ELISA (Enzyme Linked Immuno Sorbent Assay)
  • immunological assay uses enzyme linked labeling
  • calculate the potency of the analyte relative to the standard
  • Potency approval assures drug has the necessary effects on the body
  • Bond Affinity
  • strength of antigen - antibody bond
  • Radioimmunoassay.
  • target antigens have radioactive labels which the monoclonal antibodies bind to
  • second antigen is added without radioactive labels
  • competition between the two antigens can be used to determine binding affinity.
  • Affinity strength of Trastuzumab should be in line with the reference material
  • Appearance
  • Color, opalescence,& clarity must match reference sample
  • Herceptin powder comes as white to pale yellow
  • Opalescence and clarity can be assayed using a spectrophotometer
  • Identity
  • sequence and binding structure
  • Peptide Mapping by RP-HPLC
  • reverse phase - high performance liquid chromatography
  • cleave peptide bonds
  • chromatographic separation of the peptides
  • analysis done in parallel with the reference
  • confirms that no changes to the primary structure have taken place
  • MALDI (matrix assisted laser desorption/ionization) Mass Spectrometry
  • analyte is put into a crystal matrix which causes the molecules to ionize
  • laser then hits the matrix and the energy transfer causes the molecules to enter gas phase
  • high electric field, causes it to propel into a flight tube where a detector sequences them

Assays

  • Purity
  • free of unwanted substances
  • PAGE (Polyacrylamide Gel Electrophoresis)
  • uses polyacrylamide as the matrix for electrophoresis
  • treated with sodium dodecyl in order to make it negative
  • stained, purity would be indicated by bands matching those or the reference material
  • IEC (ion exchange chromatography)
  • rate of passage through the column is determined by particle attraction
  • results should match the reference sample
  • Safety
  • endotoxin, pyrogen, microbe free
  • LAL (limulus amebocyte lysate) method
  • amebocytes from horseshoe crab blood used to detect pyrogens and endotoxins
  • three types of LAL: chromogenic, turbidimetric, gel clot